Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.
about
Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study.Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantationMulti-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioningEffect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignanciesOptimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidatesMyeloid leukemia: are we getting better?Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT.Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial.Bone marrow transplantation and acute myeloid leukemia: Brazilian guidelines.Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial.Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia WConcise review: the role of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia.Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies.Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.Hematopoietic stem cell transplantation for acute myeloid leukemia: to whom, when, and how.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?Reduced-intensity conditioned allogeneic SCT in adults with AML.Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis.Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation.Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia.Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50 years of age: a systematic review and meta-analysis.Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant-related mortality in allogeneic HSCT.Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission.Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2.Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome.Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers.Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation.Outcome of allogeneic stem cell transplantation in myelodysplastic syndrome patients: prognostic implication of monosomal karyotype.Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation.Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes.Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect?
P2860
Q33737884-F1E4BC2D-34A2-4DBA-8085-36D7C8FDE0EEQ33764825-698DF228-5906-4520-B92F-D0CE2EB6C10EQ34402494-D4B55AE1-F749-4321-B21C-5B374A440B45Q34409335-45774CA1-1709-4F54-93D6-A87F7BFDB5E6Q34463645-778F6309-C5A4-40FC-8AEF-A22C2770C535Q34514273-1F99362B-001C-49B3-B4DA-5CD003CD2829Q35054842-01B6F7B7-F5F8-47E1-A479-21E8BB9FAFBDQ35193735-FB0B5CD4-9B26-43D3-B36A-437EDF8E16BCQ35285087-DABF0836-F772-420D-943E-E5B686504FC8Q35800814-A862053A-00FE-4063-8B32-4E4E218927D8Q36715911-D3E3B914-3122-4B77-AA4A-860DF0644235Q36753274-13EAF78D-BEDE-4225-A2B5-4F165B5590CFQ36821646-0CDBF137-3A29-4910-887F-C50F6047A6B8Q37000485-06AF6F9F-0635-40B7-9402-C15AEA0224D6Q37602434-7CEDE39E-E756-4C2E-9041-8781F057CA12Q38015268-38C62C41-B300-47FD-A9AE-C333FBC69942Q38095833-6444E5FE-877A-4432-9242-7F126133ED0FQ38098957-04B85B94-5248-47E9-8DD1-C63167BCA4EFQ38130168-56868E57-7D75-4CB1-9D0F-E612E427E889Q38199056-1EEA0098-874D-493B-A78F-AF535F505AE5Q38366632-1A8E20E8-EE54-4D1E-A1F7-4FBAB85A885EQ38488058-EC3C964C-B740-4360-A02B-115B8B10A13EQ38604900-4D60CCF7-4D7F-40DB-B868-09BE995C0572Q38937601-F152BAF4-EDC0-4339-B224-1E7A6749CCA3Q38952815-652DAEC4-9971-4B66-87B7-809DC5A22316Q39282540-DC42D15B-E83C-4EE8-B396-70B1B6A3BC79Q40129891-EAD5BAFD-A984-4B05-8E06-DBD0C4223A75Q41200444-A3E52222-48B7-4308-B84C-2C4B78409415Q41592261-08231FFB-4CE3-42FA-965E-E31F7FDAA751Q43429437-4D19166A-440D-4374-AF16-06868DEDAC3BQ44425255-32827DB5-D18E-4A21-BC62-06FBC88B78F4Q46103183-F1A625D9-D8C2-46CC-B4E9-A6386138615BQ47419036-E01DC736-1299-454C-8121-96ECAC3CA352Q48069751-3E42470C-C3F4-4A06-9D30-C2958DDCF609Q50494816-A7ED3C13-925F-4F3F-B2C1-197CB6DDA757Q54179395-7F4C70D8-5956-479E-94AD-6FE06AFB2684
P2860
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Myeloablative reduced-toxicity ...... hrough eighth decades of life.
@ast
Myeloablative reduced-toxicity ...... hrough eighth decades of life.
@en
Myeloablative reduced-toxicity ...... hrough eighth decades of life.
@nl
type
label
Myeloablative reduced-toxicity ...... hrough eighth decades of life.
@ast
Myeloablative reduced-toxicity ...... hrough eighth decades of life.
@en
Myeloablative reduced-toxicity ...... hrough eighth decades of life.
@nl
prefLabel
Myeloablative reduced-toxicity ...... hrough eighth decades of life.
@ast
Myeloablative reduced-toxicity ...... hrough eighth decades of life.
@en
Myeloablative reduced-toxicity ...... hrough eighth decades of life.
@nl
P2093
P2860
P1476
Myeloablative reduced-toxicity ...... hrough eighth decades of life.
@en
P2093
Alexandre Chiattone
Borje S Andersson
Chitra Hosing
Fabio Kerbauy
Gabriela Rondon
Gheath Alatrash
Leandro de Padua Silva
Lianchun Xiao
Marcos de Lima
Matteo Pelosini
P2860
P304
P356
10.1016/J.BBMT.2011.02.007
P577
2011-02-18T00:00:00Z